PMID- 11574912
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20071115
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 184
IP  - 8
DP  - 2001 Oct 15
TI  - Secondary mutations in the protease region of human immunodeficiency virus and 
      virologic failure in drug-naive patients treated with protease inhibitor-based 
      therapy.
PG  - 983-91
AB  - The role of mutations in protease (PR) and reverse-transcriptase (RT) of human 
      immunodeficiency virus (HIV) in predicting virologic failure was assessed in 248 
      antiretroviral-naive HIV-positive patients who began a PR inhibitor-containing 
      antiretroviral regimen. Genotypic testing was performed on plasma samples stored 
      before the start of therapy. Twenty-seven patients (10.9%) had mutations in the 
      RT, 5 (2%) carried primary mutations in the PR, and 131 (52.8%) showed only 
      secondary PR mutations. Virologic failure at week 24 occurred in 62 (25.0%) of 
      248 patients. There was a statistically significant correlation between virologic 
      failure and the number of PR mutations (P= .04, chi(2) test). Mutations at codons 
      10 and 36 of PR (present in 39.3% and 40.0% of patients in whom treatment failed, 
      respectively) were identified by stepwise logistic regression as the strongest 
      predictors of virologic failure (odds ratio, 2.20; 95% confidence interval, 
      1.30-3.75; P= .004). If confirmed in independent studies, this result may justify 
      the increased use of HIV genotyping in drug-naive patients requiring 
      antiretroviral therapy.
FAU - Perno, C F
AU  - Perno CF
AD  - Istituto di Ricovero e Cura a Carattere Scientifico L. Spallanzani, and 
      Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, 
      Italy. cf.perno@uniroma2.it
FAU - Cozzi-Lepri, A
AU  - Cozzi-Lepri A
FAU - Balotta, C
AU  - Balotta C
FAU - Forbici, F
AU  - Forbici F
FAU - Violin, M
AU  - Violin M
FAU - Bertoli, A
AU  - Bertoli A
FAU - Facchi, G
AU  - Facchi G
FAU - Pezzotti, P
AU  - Pezzotti P
FAU - Cadeo, G
AU  - Cadeo G
FAU - Tositti, G
AU  - Tositti G
FAU - Pasquinucci, S
AU  - Pasquinucci S
FAU - Pauluzzi, S
AU  - Pauluzzi S
FAU - Scalzini, A
AU  - Scalzini A
FAU - Salassa, B
AU  - Salassa B
FAU - Vincenti, A
AU  - Vincenti A
FAU - Phillips, A N
AU  - Phillips AN
FAU - Dianzani, F
AU  - Dianzani F
FAU - Appice, A
AU  - Appice A
FAU - Angarano, G
AU  - Angarano G
FAU - Monno, L
AU  - Monno L
FAU - Ippolito, G
AU  - Ippolito G
FAU - Moroni, M
AU  - Moroni M
FAU - d' Arminio Monforte, A
AU  - d' Arminio Monforte A
CN  - Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20010830
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Antiviral Agents)
RN  - EC 3.4.23.- (HIV Protease)
SB  - IM
CIN - J Infect Dis. 2002 May 1;185(9):1376; author reply 1376-7. PMID: 12001062
CIN - J Infect Dis. 2002 Jun 15;185(12):1844-6. PMID: 12085340
MH  - Acute Disease
MH  - Antiretroviral Therapy, Highly Active
MH  - Antiviral Agents/therapeutic use
MH  - Chronic Disease
MH  - Cohort Studies
MH  - Databases as Topic
MH  - Genotype
MH  - HIV Infections/*drug therapy/transmission
MH  - HIV Protease/*genetics
MH  - Humans
MH  - *Mutation
MH  - Odds Ratio
MH  - Treatment Failure
EDAT- 2001/09/28 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/09/28 10:00
PHST- 2001/01/18 00:00 [received]
PHST- 2001/06/21 00:00 [revised]
PHST- 2001/09/28 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/09/28 10:00 [entrez]
AID - JID010068 [pii]
AID - 10.1086/323604 [doi]
PST - ppublish
SO  - J Infect Dis. 2001 Oct 15;184(8):983-91. doi: 10.1086/323604. Epub 2001 Aug 30.